Blurred Lines – How Life Science Companies Can Keep The FTC, FDA, And Competition From Challenging Their Native Advertising

Event Details


February 24, 2016

Add To Calendar



Native advertising – advertising that looks very similar to the news and entertainment content that surrounds it – is a hot topic these days for marketers, regulatory affairs, and in-house counsel of life science companies. The Federal Trade Commission’s recently issued Enforcement Policy Statement on Deceptively Formatted Advertisements demonstrates that it is serious about stopping consumer deception from such advertisements. Moreover, competitors may use a combination of state and federal law in court to challenge native advertisements as an unfair and deceptive form of competition. And don’t forget about the Food and Drug Administration and its promotional rules.

Register now to join AGG partners, Anuj Desai (Intellectual Property Practice Team) and Alan Minsk (Food and Drug Practice Team) for a complimentary, one-hour webinar that focuses on the potential risks that native advertising poses for life science companies, and learn how you can minimize those risks while continuing to engage in native advertising.

Credits: This webinar is pending CLE credit approval by the State Bar of Georgia.